Nadine Nagy

Nadine Nagy, PhD, Instructor, Department of Medicine, Stanford University School of Medicine

Research Description: Dr. Nagy studies how immune responses are regulated in inflamed tissues with a particular focus on autoimmune, type 1 diabetes (T1D). In her research, she has identified a critical role for hyaluronan (HA), an extracellular matrix polymer abundant in inflamed tissues, in the development of T1D. She has found that HA accumulates in pancreatic islets during the progression to autoimmune insulitis in T1D as well as in mouse models of the disease. Further, she has identified that a drug called 4-methylumbelliferone (4-MU), known to inhibit HA production, can reverse the progression to autoimmune diabetes in animal models. Dr. Nagy has found that oral 4-MU reduces accumulation of HA in pancreatic islets, restores normal glycemic control, and suspends the progression to autoimmunity in mouse models of T1D. She was recently awarded a Pilot and Feasibility Award from the Stanford DRC for 2017-2018. Her research goals are to understand the biology of insulitis and to develop novel tools to prevent T1D. Her plans are to become an independent investigator in an academic setting in the next 1-2 years.

Selected relevant publications (Stanford DRC Members in BOLD):

  1. M Bogdani, PY Johnson, S Potter-Perigo, N Nagy, AJ Day, PL Bollyky, TN Wight. Hyaluronan and hyaluronan-binding proteins accumulate in both human type 1 diabetic islets and lymphoid tissues and associate with inflammatory cells in insulitis. Diabetes 63:2727-43, 2014.
  2. N Nagy, G Kaber, PY Johnson, JA Gebe, A Preisinger, BA Falk, VG Sunkari, MD Gooden, RB Vernon, M Bogdani, HF Kuipers, AJ Day, DJ Campbell, TN Wight, PL Bollyky. Inhibition of hyaluronan synthesis restores immune tolerance during autoimmune insulitis. J Clin Invest 125:3928-40, 2015.
  3. HF Kuipers*, N Nagy*, SM Ruppert, VG Sunkari, PL Marshall, JA Gebe, HD Ishak, SG Keswani, J Bollyky, AR Frymoyer, TN Wight, L Steinman, PL Bollyky. The pharmacokinetics and dosing of oral 4-methylumbelliferone for inhibition of hyaluronan synthesis in mice. Clin Exp Immunol. 185:372-81, 2016     *authors contributed equally